← Therapy pipeline
Investigational · Obesity development

Survodutide

BI 456906 · Boehringer Ingelheim / Zealand Pharma

Glucagon/GLP-1 dual agonist studied in obesity, type 2 diabetes, and liver disease.

GLP-1glucagon
Other study areas
Type 2 diabetesLiver disease (MASLD / MASH)Cardiovascular outcomes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 9, 2026
SponsorBoehringer Ingelheim / Zealand Pharma
TargetsGLP-1 + glucagon
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

SYNCHRONIZE-2Mean body-weight reductionBody weight decreased 13.1% · 76 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed Phase 3 results

Mean body-weight reduction · 76 weeks

Study focus: Weight management with type 2 diabetes

Survodutide
13.1%
Placebo
3.1%

Adults with obesity or overweight and type 2 diabetes · Up to 6.0 mg once weekly vs placebo · Trial N=755 · Efficacy estimand (assumes continued treatment). Results & methods ↗ · Publication ↗

Maximum-dose efficacy-estimand result (“up to”); treatment-regimen estimates include the effects of treatment discontinuation. In SYNCHRONIZE-2, 18% stopped treatment because of gastrointestinal adverse events versus 1.2% with placebo.

SYNCHRONIZE-CVOT · cardiovascular safetyFive-point MACE hazard ratio versus placeboFive-point MACE hazard ratio versus placebo: HR 0.89 · Event-driven trial · Phase 3
Phase 3 · Injection · Sponsor-reported primary estimate; Lancet publication linked

Five-point MACE hazard ratio versus placebo · Event-driven trial

Study focus: Cardiovascular / kidney outcomes

HR 0.89 (95% CI 0.67–1.18); p<0.0001 for noninferiority.

Survodutide versus placebo
HR 0.89

Adults with overweight or obesity and established cardiovascular disease, chronic kidney disease or elevated cardiovascular risk · Survodutide 3.6 or 6.0 mg once weekly versus placebo · Trial N=5530 · Treatment-regimen estimand; prespecified noninferiority endpoint. Results & methods ↗ · Publication ↗

The confidence interval includes 1.0: superiority and cardiovascular risk reduction were not established. Five-point MACE includes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, ischemia-related coronary revascularization and heart-failure events. ClinicalTrials.gov has no results posted; the numerical estimate shown comes from the sponsor’s November 9 report.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

SYNCHRONIZE-2 · HbA1cHbA1c reduction from baselineHbA1c decreased 1.21 percentage points · 76 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed Phase 3 results

HbA1c reduction from baseline · 76 weeks

Study focus: Glycemic control in type 2 diabetes

Survodutide
1.2 percentage points
Placebo
0 percentage points

Adults with obesity or overweight and type 2 diabetes · Up to 6.0 mg once weekly vs placebo · Trial N=755 · Efficacy estimand; baseline HbA1c 7.4%. Results & methods ↗ · Publication ↗

Maximum-dose efficacy-estimand result (“up to”); treatment-regimen estimates include the effects of treatment discontinuation.

SYNCHRONIZE-1Mean body-weight reductionBody weight decreased 13% · 76 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight reduction · 76 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
13%
Placebo / comparator
5.4%

Adults with obesity or overweight and a weight-related complication, without diabetes · 6 mg once weekly vs placebo · Trial N=725 · Treatment-regimen estimand. Results & methods ↗ · Publication ↗

This analysis includes the effects of treatment discontinuation. Adherence-based estimates answer a different question; the 16.6% headline should not be substituted into this comparison.

SYNCHRONIZE-MASLD · primary liver-fat endpointParticipants with ≥30% liver-fat reduction by MRI-PDFFParticipants with ≥30% liver-fat reduction by MRI-PDFF: 68.5% · 48 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Participants with ≥30% liver-fat reduction by MRI-PDFF · 48 weeks

Study focus: Liver outcomes (MASLD / MASH)

Survodutide
68.5%
Placebo
28.6%

Adults with obesity or overweight and at-risk MASLD · 6 mg once weekly vs placebo · Trial N=216 · Treatment-regimen estimand. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same study · body-weight endpointAt 48 weeks, mean body-weight reduction was 8.7% versus 1.4% with placebo (treatment-regimen estimand).

The primary endpoint was a relative reduction in MRI-PDFF liver fat; it is not a liver-histology or approval outcome.

Phase 2 obesity dose-finding studyMean body-weight reductionBody weight decreased 14.9% · 46 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight reduction · 46 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
14.9%
Placebo / comparator
2.8%

Adults with overweight or obesity without diabetes · 4.8 mg once weekly vs placebo · Trial N=387 · Planned-treatment analysis. Results & methods ↗

Dose-finding Phase 2 study; this 4.8 mg arm is one within-study comparison.

Phase 2 MASH histology studyParticipants with MASH improvement without fibrosis worseningParticipants with MASH improvement without fibrosis worsening: 62% · 48 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Participants with MASH improvement without fibrosis worsening · 48 weeks

Study focus: Liver outcomes (MASLD / MASH)

Survodutide 4.8 mg
62%
Placebo
14%

Adults with biopsy-confirmed MASH and F1–F3 fibrosis · 4.8 mg once weekly vs placebo · Trial N=293 · Primary histologic endpoint. Results & methods ↗ · Publication ↗

Dose-ranging Phase 2 liver study. Histologic MASH response is distinct from obesity-stage evidence and is not an approval.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

Survodutide Phase 2 T2D dose-finding studyHbA1c change from baseline at week 16HbA1c decreased 1.71 percentage points · 16 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

HbA1c change from baseline at week 16 · 16 weeks

Study focus: Glycemic control in type 2 diabetes

Survodutide 1.8 mg once weekly
1.7 percentage points
Placebo
0.2 percentage points

Adults with type 2 diabetes on metformin · 1.8 mg once weekly vs placebo · Trial N=413 · Adjusted mean change; primary glycemic outcome. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same study · body-weight outcomeAt the highest dose (1.8 mg twice weekly), mean body-weight change was −8.7% versus −5.3% with semaglutide 1.0 mg weekly at week 16.

Dose-finding Phase 2 study; this diabetes population differs from the obesity-only trials.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3Initiated
Milestone → next

Latest: SYNCHRONIZE-CVOT met its cardiovascular-safety noninferiority endpoint; results reported November 9, 2026 with a linked Lancet publication. This does not establish cardiovascular superiority.

Next: Further Phase 3 metabolic and liver studies continue; SYNCHRONIZE-T2D evaluates glycemic control in adults with type 2 diabetes.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies5 records

Phase 3

SYNCHRONIZE-1

Weight management without type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with obesity or overweight without type 2 diabetes; 76-week chronic weight-management study. Peer-reviewed results published in 2026.

Phase 3

SYNCHRONIZE-2

Weight management with type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes; 76-week Phase 3 study. Peer-reviewed weight and glycemic results published in 2026.

Phase 3

SYNCHRONIZE-HERA

Weight management during or after menopause
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered Phase 3 study in women going through or after menopause; not yet recruiting.

Phase 3b

SYNCHRONIZE-START

Weight management
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered open-label, nonrandomized pragmatic Phase 3b study; not yet recruiting.

Phase 2 studies2 records

Phase 2

Survodutide type 2 diabetes dose-finding study

Glycemic control and weight outcomes in type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with type 2 diabetes on metformin; 16-week dose-finding study compared survodutide with placebo and open-label semaglutide. Published results in Diabetologia.

Phase 2

Survodutide obesity dose-finding study

Weight management
Study: CompletedResults: Published results linked aboveStatus reviewed November 2026

Adults with overweight or obesity without diabetes; 46 weeks. At 4.8 mg weekly, mean weight change was −14.9% versus −2.8% with placebo in the planned-treatment analysis.

Related conditions and outcomes

Phase 3 studies5 records

Phase 3

LIVERAGE

Liver outcomes (MASLD / MASH)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with MASH and moderate-to-advanced fibrosis, stages F2–F3. Separate global liver-disease program.

Phase 3

LIVERAGE-Cirrhosis

Liver outcomes (MASLD / MASH)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with compensated MASH cirrhosis, stage F4. Separate global liver-disease program.

Phase 3

SYNCHRONIZE-CVOT

Cardiovascular outcomes
Study: CompletedResults: Published trial; sponsor-reported primary estimate shownStatus reviewed November 2026

Completed randomized Phase 3 cardiovascular-safety trial, N=5,530. Noninferiority established; superiority not established. No results posted to the registry; external results reported November 9, 2026.

Phase 3

SYNCHRONIZE-MASLD

Liver outcomes (MASLD / liver fat)
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with obesity and at-risk MASLD, including noninvasive-test-defined disease or recent biopsy-confirmed MASH. Published 48-week liver-fat and weight results in 2026.

Phase 3

SYNCHRONIZE-T2D

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Glycemic-control study in adults with type 2 diabetes receiving diet and physical activity alone or with oral antidiabetic medicines or insulin.

Phase 2 studies2 records

Phase 2

ELEVATE-LIVER

Cardiac structure and function in liver disease
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered Phase 2 study of cardiac structure/function in a liver-disease population; not yet recruiting. Weight is not its primary outcome.

Phase 2

Survodutide MASH and fibrosis study

Liver outcomes (MASLD / MASH)
Study: CompletedResults: Published results linked aboveStatus reviewed November 2026

Biopsy-confirmed MASH with F1–F3 fibrosis; 48-week histology study. Published in 2024; this is a liver-disease result, not the obesity stage.